UY27614A1 - Formulaciones estabilizadas de adenovirus - Google Patents

Formulaciones estabilizadas de adenovirus

Info

Publication number
UY27614A1
UY27614A1 UY27614A UY27614A UY27614A1 UY 27614 A1 UY27614 A1 UY 27614A1 UY 27614 A UY27614 A UY 27614A UY 27614 A UY27614 A UY 27614A UY 27614 A1 UY27614 A1 UY 27614A1
Authority
UY
Uruguay
Prior art keywords
adenovirus
stabilized formulations
adenoviruses
pharmaceutical
particular recombinant
Prior art date
Application number
UY27614A
Other languages
English (en)
Inventor
Erno Pungor
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27614A1 publication Critical patent/UY27614A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)

Abstract

Un método para estabilizar composiciones que contienen virus transportados por aire, en particular adenovirus, en particular adenovirus recombinantes, que comprende la adición a las comisiciónes de un detergente no iónico que comprende un grupo alquilo y un grupo polietilenglicol (PEG) También composiciones farmacéuticas y de otro tipo de adenovirus, en particular adenovirus recombinantes adecuados para los métodos de terapia génica, que comprenden dichos detergentes.
UY27614A 2002-01-18 2003-01-17 Formulaciones estabilizadas de adenovirus UY27614A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34922202P 2002-01-18 2002-01-18

Publications (1)

Publication Number Publication Date
UY27614A1 true UY27614A1 (es) 2003-08-29

Family

ID=27613260

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27614A UY27614A1 (es) 2002-01-18 2003-01-17 Formulaciones estabilizadas de adenovirus

Country Status (18)

Country Link
US (1) US20030232018A1 (es)
EP (1) EP1465664A1 (es)
JP (1) JP2005515245A (es)
KR (1) KR20040077878A (es)
CN (1) CN1617745A (es)
AR (1) AR038153A1 (es)
BR (1) BR0306925A (es)
CA (1) CA2469721A1 (es)
IL (1) IL162404A0 (es)
MX (1) MXPA04006995A (es)
NO (1) NO20043418L (es)
PE (1) PE20030851A1 (es)
PL (1) PL371261A1 (es)
RU (1) RU2004125283A (es)
TW (1) TW200307750A (es)
UY (1) UY27614A1 (es)
WO (1) WO2003061708A1 (es)
ZA (1) ZA200406547B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
WO2012075379A2 (en) * 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CN105188745B (zh) 2013-04-25 2019-10-18 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
EA036412B1 (ru) * 2015-10-06 2020-11-09 Янссен Вэксинс Энд Превеншн Б.В. Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса
WO2017174564A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
AU2017264562B2 (en) 2016-05-12 2023-03-09 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
JP2019523644A (ja) 2016-05-30 2019-08-29 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された融合前ｒｓｖ ｆタンパク質
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
JP6721797B2 (ja) 2017-02-09 2020-07-15 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 異種遺伝子発現のための強力で短いプロモーター
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
KR20220134622A (ko) 2020-01-31 2022-10-05 베쓰 이스라엘 디코니스 메디칼 센터 인크 코로나바이러스 감염 예방 및 치료용 조성물 및 방법 - sars-cov-2 백신
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2144040A1 (fr) * 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US6485958B2 (en) * 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
ID28298A (id) * 1998-02-17 2001-05-10 Schering Corp Komposisi yang mengandung virus dan metode untuk memekatkan preparat-preparat virus
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1150712B1 (en) * 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations
WO2001066137A1 (en) * 2000-03-07 2001-09-13 Merck & Co., Inc. Adenovirus formulations

Also Published As

Publication number Publication date
US20030232018A1 (en) 2003-12-18
CA2469721A1 (en) 2003-07-31
WO2003061708A1 (en) 2003-07-31
EP1465664A1 (en) 2004-10-13
PE20030851A1 (es) 2004-01-01
CN1617745A (zh) 2005-05-18
TW200307750A (en) 2003-12-16
JP2005515245A (ja) 2005-05-26
ZA200406547B (en) 2006-06-24
PL371261A1 (en) 2005-06-13
IL162404A0 (en) 2005-11-20
NO20043418L (no) 2004-08-17
AR038153A1 (es) 2004-12-29
BR0306925A (pt) 2004-11-09
KR20040077878A (ko) 2004-09-07
MXPA04006995A (es) 2005-07-13
RU2004125283A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
UY27614A1 (es) Formulaciones estabilizadas de adenovirus
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
ECSP034439A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
BR0205767B1 (pt) Sais de sulfônio, composições curáveis por radiação, formulações líquidas, e, método para a preparação dos sais de sulfônio
AR029851A1 (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
BR112019009113A2 (pt) formulações de vírus adenoassociado
AR061894A1 (es) Vacunas para malaria
BRPI0718688A8 (pt) Composições de baixa irritação e métodos para preparar as mesmas
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
UY27854A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
ATE382057T1 (de) Stabile formulierung von modifiziertem glp-1
NO20044808L (no) Heterosykliske sulfonamider som er hepatitt C virus inhibitorer
DE69940769D1 (de) Orale flüssige zusammensetzungen
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
AR059257A1 (es) Genes para mejorar la eficiencia de la utilizacion de nitrogeno en los cultivos
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
ECSP066959A (es) Compuestos macrociclicos como inhibidores de la replicación viral
NO20062948L (no) Promotere for ekspresjon i modifisert vaccinia-virus Ankara
ES2169654B1 (es) Agente desfoliante
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
BR112015007879A2 (pt) inibidores do vírus da hepatite c
CO5590911A2 (es) Composiciones farmaceuticas a base de derivados de azetidina
ES2185417T3 (es) Excipientes para usar en formulaciones farmaceuticas de virus adeno-asociados, y formulaciones farmaceuticas producidas con ellos.
BRPI0416950A (pt) métodos para remover vìrus de uma composição do fator vii lìquida, para inativar vìrus em uma composição do fator vii lìquida, e para eliminar em alto nìvel a presença de vìrus ativos em uma composição do fator vii lìquida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161108